Loading clinical trials...

Intensive Cancer Screening After Cryptogenic Stroke | Clinical Trials | Clareo Health

RECRUITINGNA

Intensive Cancer Screening After Cryptogenic Stroke

Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial

NCT05733416•Ottawa Hospital Research Institute

Summary

The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•adults ≥18 years
•presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)
•patient or delegate willing and able to provide informed consent.

Exclusion Criteria

•contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes)
•active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)

Locations (1)

The Ottawa Hospital

Ottawa, Ontario, Canada

Key Dates

Start Date

September 1, 2023

Primary Completion Date

January 1, 2027

Completion Date

January 1, 2027

Last Updated

July 31, 2025

Enrollment

ESTIMATED participants

Conditions

Occult Cancer

Interventions

FDG PET/CT

DIAGNOSTIC_TEST

Usual Care

DIAGNOSTIC_TEST

Contacts

Dariush Dowlatshahi, MD PhD

CONTACT

613-798-5555 ddowlat@toh.ca

Deborah Siegal, MD

CONTACT

613-737-8899 dsiegal@toh.ca

External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients

NCT07310693

Venous Thromboembolism (VTE)Occult Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 31, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions